Edition:
United Kingdom

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

85.30EUR
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
€85.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
130,735
52-wk High
€88.40
52-wk Low
€50.50

Select another date:

Wed, Apr 18 2018

BRIEF-Morphosys Announces Pricing Of IPO Of American Depositary Shares On Nasdaq

* MORPHOSYS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES (ADSS) ON NASDAQ

BRIEF-Morphosys to increase capital to implement Offering Of 8.3 mln ADS

* DGAP-ADHOC: MORPHOSYS RESOLVES A CAPITAL INCREASE TO IMPLEMENT THE OFFERING OF 8,300,000 AMERICAN DEPOSITARY SHARES (ADS) IN THE UNITED STATES

BRIEF-Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC Filing

* MORPHOSYS AG SEES U.S. IPO 8.3 MLN AMERICAN DEPOSITARY SHARES - SEC FILING

BRIEF-Morphosys Says Tremfya Approved To Treat Psoriasis In Japan

* SAYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE TO SEVERE FORMS OF PSORIASIS AND PSORIATIC ARTHRITIS IN JAPAN Source text for Eikon: Further company coverage:

BRIEF-Morphosys AG Files For U.S. IPO Of Up To $150 Mln

* MORPHOSYS AG FILES FOR U.S. IPO OF UP TO $150 MILLION – SEC FILING

BRIEF-Morphosys AG Says ‍Files Registration Statement In United States For A Proposed American Depositary Shares (ADS) Offering​

* SAYS ‍FILES REGISTRATION STATEMENT IN UNITED STATES FOR A PROPOSED AMERICAN DEPOSITARY SHARES (ADS) OFFERING​

BRIEF-Morphosys Sees EBIT Loss Widening To 110-120 Mln Euros In 2018

* ‍REVENUES 2017 UP 34% TO EUR 66.8 MILLION (GUIDANCE EUR 63 TO 66 MILLION)​

BRIEF-Morphosys Announces New Data On Tremfya

* DGAP-NEWS: MORPHOSYS ANNOUNCES THAT TREMFYA(R) (GUSELKUMAB) DATA DEMONSTRATED LONG-TERM SKIN CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS Source text for Eikon: Further company coverage:

BRIEF-Morphosys And Galapagos Present Results From Phase 1 Study With Mor106

* SAID ON SATURDAY MORPHOSYS AND GALAPAGOS PRESENT RESULTS FROM A PHASE 1 STUDY WITH MOR106 IN ATOPIC DERMATITIS AS LATE-BREAKING ABSTRACT

BRIEF-Galapagos And MorphoSys Present Results From Phase 1 Study With MOR106 In Atopic Dermatitis

* GALAPAGOS AND MORPHOSYS ANNOUNCED ON SATURDAY THAT MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS (AD) PATIENTS

Select another date: